Serum tumour M2‐pyruvate kinase as a biomarker for diagnosis and prognosis of early‐stage non–small cell lung cancer
Author:
Affiliation:
1. Department of Respiratory Medicine Nanjing Chest Hospital Nanjing China
2. Affiliated Nanjing Brain Hospital Nanjing Medical University Nanjing China
Publisher
Wiley
Subject
Cell Biology,Molecular Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.16762
Reference20 articles.
1. Cancer statistics, 2020
2. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
3. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline
4. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
5. Expression of Cripto‐1 predicts poor prognosis in stage I non‐small cell lung cancer
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Diagnostic value of artificial intelligence based on computed tomography (CT) density in benign and malignant pulmonary nodules: a retrospective investigation;PeerJ;2024-01-02
2. Elevated plasma pyruvate kinase M2 concentrations are associated with the clinical severity and prognosis of coronary artery disease;Biochemia medica;2023-12-15
3. PKM2 is a potential prognostic biomarker and related to immune infiltration in lung cancer;Scientific Reports;2023-12-14
4. Conducting polymer composite-based biosensing materials for the diagnosis of lung cancer: A review;International Journal of Biological Macromolecules;2023-12
5. Serum THBS2 is a potential biomarker for the diagnosis of non-small cell lung cancer;Journal of Cancer Research and Clinical Oncology;2023-09-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3